Marken Announces Moscow Depot
News Oct 03, 2013
Marken has announced the addition of a dedicated depot in Moscow, Russia. The depot announcement is part of Marken’s ongoing expansion of their global pharmaceutical depot network.
The Russia depot will be located within an existing GxP-compliant storage facility in Moscow, offering a secure and dedicated space near the airport.
The facility will be operated by dedicated staff trained on Marken’s global procedures and managed by the state of the art global inventory system, Solo.
The Solo operating and tracking system provides clients with 24/7 access and monitoring of its global supplies and distribution status.
The announcement follows an exhaustive search for a high-quality fully-operational depot that provides proximity to international airports and shipping lanes.
The new Moscow site is seamlessly integrated into the existing and growing Marken depot network already serving the pharmaceutical industry. It joins Marken’s current network of depots in China, Singapore, Argentina, Mexico, Germany, and the United States.
Marken’s network of pharmaceutical depot facilities and supporting IT systems are designed to provide the most flexible and efficient storage and distribution of materials for the clinical trials community. They are designed for all clinical materials, and are particularly suited for temperature-controlled, time sensitive products which are emerging in most pharmaceutical company pipelines.
Marken has a significant transportation capability in Russia, a country which remains an important clinical trial center. This new depot capability allows the company to expand its portfolio of services in the region.
Gerit Offenhauser, Marken’s Senior Vice President, Clinical Trials Distribution, said, “This co-location in Moscow offers clear market opportunities for our clients who have indicated a need for clinical trial operations in Russia and Eastern Europe. We look forward to meeting the growing needs for depot services in that part of the world.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018